BioMarin estimates FY2022 total revenue of $2.09B, VOXZOGO sales $169M

BIOMARIN PHARMACEUTICAL INC

2022-FY EPS reported $0.75 revenue$2,096,039,000

Preliminary unaudited total revenue for FY2022 estimated at $2.09 billion.
VOXZOGO contributed approximately $169 million in revenue for FY2022.
Revenue figures are preliminary and subject to completion of quarterly closing procedures.
Full FY2022 results expected to be reported in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BIOMARIN PHARMACEUTICAL INC reported the year ended December 31, 2022 results: revenue approximately $2.09 billion in total revenues (unaudited).

Period: the year ended December 31, 2022
Revenue: approximately $2.09 billion in total revenues (unaudited)
Result: preliminary results

Exact text from the filing

based on preliminary results the Company estimates that it generated approximately $2.09 billion in total revenues (unaudited) for the year ended December 31, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001193125-23-006489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.